The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
QARZIBA (Emerge Health Pty Ltd)
Product name
QARZIBA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
137 working days (255)
Active ingredients
dinutuximab beta
Registration type
NCE/NBE
Indication
QARZIBA (concentrated solution for injection) is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.